Despite the use of monoclonal antibodies (trastuzumab and pertuzumab) and HER2-targeting tyrosine kinase inhibitors (lapatinib, neratinib, and afatinib) as targeted therapies for HER2-positive bladder cancer, these single agents have failed to elicit satisfactory responses (35). The gene discussed is ERBB2; the disease is urinary bladder cancer.